Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study

View ORCID ProfileSevda Molani, Andrew M. Baumgartner, Yeon Mi Hwang, Venkata R. Duvvuri, View ORCID ProfileJason D. Goldman, View ORCID ProfileJennifer J. Hadlock
doi: https://doi.org/10.1101/2022.02.07.22270613
Sevda Molani
1Institute for Systems Biology, Seattle, Washington, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sevda Molani
Andrew M. Baumgartner
1Institute for Systems Biology, Seattle, Washington, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yeon Mi Hwang
1Institute for Systems Biology, Seattle, Washington, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Venkata R. Duvvuri
1Institute for Systems Biology, Seattle, Washington, United States of America
PhD, MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason D. Goldman
2Swedish Center for Research and Innovation, Seattle, Washington, United States of America
3Providence St. Joseph Health, Renton, Washington, United States of America
4Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, United States of America
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason D. Goldman
Jennifer J. Hadlock
1Institute for Systems Biology, Seattle, Washington, United States of America
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jennifer J. Hadlock
  • For correspondence: jhadlock{at}isbscience.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background It is important to understand how BNT162b2, mRNA-1273, and JNJ-78436735 COVID-19 vaccines, as well as prior infection, protect against breakthrough cases and reinfections. Real world evidence on acquired immunity from vaccines, and from SARS-CoV-2 infection, can help public health decision-makers understand disease dynamics and viral escape to inform resource allocation for curbing the spread of pandemic.

Methods This retrospective cohort study presents demographic information, survival functions, and probability distributions for 2,627,914 patients who received recommended doses of COVID-19 vaccines, and 63,691 patients who had a prior COVID-19 infection. In addition, patients receiving different vaccines were matched by age, sex, ethnic group, state of residency, and the quarter of the year in 2021 the COVID-19 vaccine was completed, to support survival analysis on pairwise matched cohorts.

Findings Each of the three vaccines and infection-induced immunity all showed a high probability of survival against breakthrough or reinfection cases (mRNA-1273: 0.997, BNT162b2: 0.997, JNJ-78436735: 0.992, previous infection: 0.965 at 180 days). The incidence rate of reinfection among those unvaccinated and previously infected was higher than that of breakthrough among the vaccinated population (reinfection: 0.9%; breakthrough:0.4%). In addition, 280 vaccinated patients died (0.01% all-cause mortality) within 21 days of the last vaccine dose, and 5898 (3.1 %) died within 21 days of a positive COVID-19 test.

Conclusions Despite a gradual decline in vaccine-induced and infection-induced immunity, both acquired immunities were highly effective in preventing breakthrough and reinfection. In addition, for unvaccinated patients with COVID-19, those who did not die within 90 days of their initial infection (9565 deaths, 5.0% all-cause mortality rate), had a comparable asymptotic pattern of breakthrough infection as those who acquired immunity from a vaccine. Overall, the risks associated with COVID-19 infection are far greater than the marginal advantages of immunity acquired by prior infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was funded in part by the Swedish Medical Center Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of Institute for Systems Biology gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted February 08, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study
Sevda Molani, Andrew M. Baumgartner, Yeon Mi Hwang, Venkata R. Duvvuri, Jason D. Goldman, Jennifer J. Hadlock
medRxiv 2022.02.07.22270613; doi: https://doi.org/10.1101/2022.02.07.22270613
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Time to reinfection and vaccine breakthrough SARS-CoV-2 infections: a retrospective cohort study
Sevda Molani, Andrew M. Baumgartner, Yeon Mi Hwang, Venkata R. Duvvuri, Jason D. Goldman, Jennifer J. Hadlock
medRxiv 2022.02.07.22270613; doi: https://doi.org/10.1101/2022.02.07.22270613

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (428)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3286)
  • Dentistry and Oral Medicine (362)
  • Dermatology (276)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1168)
  • Epidemiology (13349)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5140)
  • Geriatric Medicine (481)
  • Health Economics (781)
  • Health Informatics (3261)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1189)
  • Hematology (429)
  • HIV/AIDS (1015)
  • Infectious Diseases (except HIV/AIDS) (14618)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4914)
  • Nursing (262)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2517)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (542)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (549)
  • Primary Care Research (555)
  • Psychiatry and Clinical Psychology (4198)
  • Public and Global Health (7489)
  • Radiology and Imaging (1703)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (496)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (204)